Egetis Therapeutics AB (publ) (EGTX) Wins FDA OK for EMCITATE in MCT8 Deficiency

Egetis Therapeutics received FDA approval for EMCITATE (tiratricol) to treat peripheral thyrotoxicosis in MCT8 deficiency. U.S. launch is expected in 8—10 weeks; the FDA also granted a Rare Pediatric Disease Priority Review Voucher.Material DetailsContext by AI AnalystThis is a late-stage milestone…